Loryna 28 Day Shortage Update: What Patients Need to Know in 2026

If you've been struggling to fill your Loryna 28 Day prescription in 2026, you're not imagining things. While Loryna is not on the FDA's official drug shortage list, many patients nationwide are experiencing frustrating stockouts at their local pharmacies. Here's a clear-eyed update on what's happening and what you can do.

Is Loryna 28 Day in an Official FDA Shortage?

As of 2026, Loryna (manufactured by Xiromed, LLC) is not listed on the FDA's official drug shortage database. The FDA shortage list tracks specific manufacturers and NDC (National Drug Code) numbers. Because there are more than 10 generic versions of drospirenone/ethinyl estradiol 3mg/0.02mg on the market, the FDA threshold for a formal shortage declaration — that all manufacturers cannot meet demand — is rarely triggered.

However, the practical experience for many patients is one of intermittent, localized unavailability. In 2025, multiple manufacturers discontinued specific NDC formulations of drospirenone/ethinyl estradiol — including one discontinued as recently as June 2025. This disrupted supply chains and created regional stock variability.

What's Causing Loryna Availability Problems in 2026?

Several factors are contributing to Loryna availability challenges:

NDC discontinuations: Some manufacturers discontinued specific NDCs of drospirenone/ethinyl estradiol in 2025, reducing the overall supply available to distributors.

High demand: Approximately 14 million U.S. women use drospirenone-based birth control pills. Demand has grown due to the drug's unique benefits for PMDD and acne, and the ACA's no-cost contraception mandate has increased fill rates.

Generic market fragmentation: Pharmacies rotate between generics based on price and distributor availability. When a pharmacy switches from Loryna to Nikki or Vestura, patients searching for Loryna by name may think it has disappeared.

Overseas manufacturing: Loryna is manufactured by Laboratorios Leon Farma in Spain. International supply chains are more vulnerable to shipping delays, regulatory inspections, and raw material shortages than domestic manufacturing.

Which Pharmacies Are Most Affected?

Large retail chain pharmacies are most likely to experience Loryna-specific stockouts because they tend to carry a single preferred generic at a time — whichever brand their wholesaler supplies. Independent pharmacies and warehouse club pharmacies (Costco, Sam's Club) are often better positioned because they source from multiple distributors.

What Should Patients Do Right Now?

Here are the most important steps for patients managing Loryna availability issues in 2026:

Don't wait until you're out. Set a reminder to refill as soon as your insurance allows (typically when you have 7 days remaining).

Ask about generic substitution. Nikki, Vestura, Jasmiel, Lo-Zumandimine, and Gianvi all contain the exact same active ingredients as Loryna. Ask your pharmacist if one of these is in stock.

Use medfinder. medfinder calls pharmacies near you to check which ones can fill your prescription — without the hassle of calling every pharmacy yourself.

Consider 90-day supply via mail order. If your insurance plan offers mail-order pharmacy, switching to a 90-day supply dramatically reduces the risk of running into local stockouts.

Contact your prescriber proactively. If you anticipate a supply problem, call your OB-GYN or primary care provider. They may be able to call in an emergency supply or provide samples.

What If I'm Uninsured or Can't Afford Loryna?

If cost is a barrier, here's the good news: the retail price for Loryna without insurance averages around $75-$100 per pack, but GoodRx coupons can bring it down to as little as $25-$32 per pack. SingleCare coupons can reduce the price to as low as $6.20 per pack for generic drospirenone/ethinyl estradiol. Most patients with private insurance pay $0 under the ACA contraceptive mandate for generic birth control.

Will This Shortage Get Better?

The drospirenone/ethinyl estradiol market includes enough manufacturers to eventually fill gaps when one discontinues. However, the U.S. generic birth control market continues to consolidate, and the combination of strong demand and just-in-time pharmacy inventory means that localized stockouts are likely to remain a fact of life for many patients. Staying informed and proactive remains the best defense. Providers can read more in our guide: Loryna 28 Day Shortage — What Providers Need to Know in 2026.